At a glance

EIH is promoted by Evolvence Capital Ltd (“Evolvence Capital”), a Dubai based, alternative investment firm established in 2000.

• EIH is an Isle of Man incorporated, private equity fund of funds holding company focused on India. The Company give investors access to top performing fund managers and a diversified Indian private equity portfolio while mitigating issues usually associated with private equity investments, such as lack of liquidity and relatively large minimum investment size.

• EIH has committed the net offering proceeds, directly or indirectly, approximately as follows:

• 70 per cent of the net offering proceeds in the Evolvence India Fund (“EIF”);
• 10 per cent of the net offering proceeds in the Evolvence India Life Sciences Fund (“EILSF”); and
• 20 per cent of the net offering proceeds in direct investment opportunities in India

• EIH has committed to invest up to 70% of the net offering proceeds in EIF, an established private equity fund of funds with a co-investment pool focusing on growth capital in India.  Through this shareholding, investors get access to:

• invest in a diversified portfolio of Indian companies through underlying private equity funds held by EIF;
• participate in the potential future uplift in the performance of private equity funds that have been investing in Indian companies for the past three years and generated superior returns
• gain exposure to co-investments to be made alongside the private equity funds in individual Indian companies. EIF has to date made four co-investments and the pipeline for such investments remains robust; and

• EILSF is a new fund that has been created to make private equity investments in life sciences businesses that are either based in India, or have material business activities in India. The target fund size is US$150 million.

• The fund has completed its first investment of $ 5 million in a cancer care services company based in Bangalore, India.

• The Life Sciences sector in India has annual revenue of approximately US$8.8 billion and is growing rapidly. The three main market drivers are:

• generic drugs – the Indian generic industry accounts for 22 per cent of the generic world market. Low cost production gives India an edge over other generic-producing nations.
• domestic demand – in a society with a fast growing, emerging middle class, healthcare expenditure is growing rapidly.
• R&D outsourcing – India is expected to be a leading player in the field of outsourcing of certain aspects of the R&D process to lower cost countries.

• EIH will also make direct investments into high growth sectors in India such as Financial Services, Infrastructure, Manufacturing and Retail. EIH has access to proprietary deal sourcing through its investment advisors based in India.

The Company intends to distribute a substantial portion of its distributable profits as dividends. The Company’s longer term target is to provide investors with a dividend yield of six per cent per annum.